This HTML5 document contains 51 embedded RDF statements represented using HTML+Microdata notation.

The embedded RDF content will be recognized by any processor of HTML5 Microdata.

Namespace Prefixes

PrefixIRI
dctermshttp://purl.org/dc/terms/
n12http://localhost/temp/predkladatel/
n13http://linked.opendata.cz/resource/domain/vavai/projekt/
n6http://linked.opendata.cz/resource/domain/vavai/riv/tvurce/
n18http://linked.opendata.cz/ontology/domain/vavai/
shttp://schema.org/
n5http://linked.opendata.cz/ontology/domain/vavai/riv/
skoshttp://www.w3.org/2004/02/skos/core#
n15http://linked.opendata.cz/resource/domain/vavai/vysledek/RIV%2F62156489%3A43210%2F10%3A00184801%21RIV12-GA0-43210___/
n2http://linked.opendata.cz/resource/domain/vavai/vysledek/
rdfhttp://www.w3.org/1999/02/22-rdf-syntax-ns#
n10http://linked.opendata.cz/ontology/domain/vavai/riv/klicoveSlovo/
n14http://linked.opendata.cz/ontology/domain/vavai/riv/duvernostUdaju/
xsdhhttp://www.w3.org/2001/XMLSchema#
n17http://linked.opendata.cz/ontology/domain/vavai/riv/aktivita/
n8http://linked.opendata.cz/ontology/domain/vavai/riv/jazykVysledku/
n16http://linked.opendata.cz/ontology/domain/vavai/riv/druhVysledku/
n11http://linked.opendata.cz/ontology/domain/vavai/riv/obor/
n7http://reference.data.gov.uk/id/gregorian-year/

Statements

Subject Item
n2:RIV%2F62156489%3A43210%2F10%3A00184801%21RIV12-GA0-43210___
rdf:type
skos:Concept n18:Vysledek
dcterms:description
Rakovina prostaty je druhou nejčastější příčinou úmrtí u mužů. V současné době, prostatický specifický antigen (PSA) je pouze nádorový marker pro karcinom detekci. Tento nádorový marker má vysokou citlivost, ale nižší úroveň specifičnosti, tak to může být zvýšena buď v zánětu nebo v hyperplazii prostaty. Je žádoucí najít nové markery s vyšší úrovní specifičnosti. Metalothioneinu (MT) a alfa-methylacyl-CoA (AMACR) racemase by mohly být tyto markery. Vyjádření obou těchto proteinů je velmi neregulované v karcinomu prostaty. MT vyšší hladiny největší pravděpodobností v důsledku dysbalance zinku metabolismu u tohoto onemocnění, a z důvodu zvýšení AMACR je stále neznámý. V naší práci jsme analyzovali hladiny MT, PSA a AMACR na buněčné linie odvozené od karcinomu prostaty - LNCaP, PC-3 a 22RVL, které byly ve srovnání s prostatou buněčné linie odvozené od běžných PNT1A prostaty epitelu. Pro analýzu jsme použili immunoseparation techniky, western blotting a SDS-PAGE. Kromě této klasické metody molekulární biologie jsme použili nové elektrochemické detekce a kapilární elektroforézy na čipu. Zjistili jsme významné zvýšení MT, AMACR a PSA v prostatě linií nádorových buněk, podobně jako v reálných vzorcích krve od pacientů s karcinomem prostaty. Tato studie poskytuje nové důležité informace o expresi MT, PSA a AMACR v prostatě nádorových buněčných liniích a Popisuje aplikace elektrochemických metod pro jejich detekci Prostate cancer is second leading cause of death among men. In the present time, prostate specific antigen (PSA) is the only tumor marker used for carcinoma detection. This tumor marker has high level of sensitivity, but lower level of specificity, so it can be increased either in inflammation or in prostate hyperplasia. It is desirable to find a new markers with higher level of specificity. Metallothionein (MT) and alpha-methylacyl-CoA (AMACR) racemase could be such markers. Expression of both of these proteins is highly unregulated in prostate cancer. MT levels are elevated most likely due to disbalance of zinc metabolism in this disease, and reason of elevation of AMACR is still unknown. In our work we analyzed levels of MT, PSA and AMACR in cell lines derived from prostate carcinoma - LNCaP, PC-3 and 22RVL, which were compared to prostate cell line PNT1A derived from normal prostate epithelium. For analysis we used immunoseparation techniques, western blotting and SDS-PAGE. In addition to this clasical methods of molecular biology we used novel electrochemical detection and capillary electrophoresis on the chip. We found significant elevation of MT, AMACR and PSA in prostate tumor cell lines similarly as in real blood samples from patients with prostate carcinoma. This study provides important new information about expression of MT, PSA and AMACR in prostate tumor cell lines and desribes application of electrochemical methods for their detection. Prostate cancer is second leading cause of death among men. In the present time, prostate specific antigen (PSA) is the only tumor marker used for carcinoma detection. This tumor marker has high level of sensitivity, but lower level of specificity, so it can be increased either in inflammation or in prostate hyperplasia. It is desirable to find a new markers with higher level of specificity. Metallothionein (MT) and alpha-methylacyl-CoA (AMACR) racemase could be such markers. Expression of both of these proteins is highly unregulated in prostate cancer. MT levels are elevated most likely due to disbalance of zinc metabolism in this disease, and reason of elevation of AMACR is still unknown. In our work we analyzed levels of MT, PSA and AMACR in cell lines derived from prostate carcinoma - LNCaP, PC-3 and 22RVL, which were compared to prostate cell line PNT1A derived from normal prostate epithelium. For analysis we used immunoseparation techniques, western blotting and SDS-PAGE. In addition to this clasical methods of molecular biology we used novel electrochemical detection and capillary electrophoresis on the chip. We found significant elevation of MT, AMACR and PSA in prostate tumor cell lines similarly as in real blood samples from patients with prostate carcinoma. This study provides important new information about expression of MT, PSA and AMACR in prostate tumor cell lines and desribes application of electrochemical methods for their detection.
dcterms:title
Determination of novel tumor markers in prostate carcinoma Stanovení nového rakovinného markeru u prostatických karcinomů Determination of novel tumor markers in prostate carcinoma
skos:prefLabel
Stanovení nového rakovinného markeru u prostatických karcinomů Determination of novel tumor markers in prostate carcinoma Determination of novel tumor markers in prostate carcinoma
skos:notation
RIV/62156489:43210/10:00184801!RIV12-GA0-43210___
n5:aktivita
n17:P
n5:aktivity
P(GP301/09/P436)
n5:cisloPeriodika
1
n5:dodaniDat
n7:2012
n5:domaciTvurceVysledku
n6:3931315 n6:4995775 n6:2104237
n5:druhVysledku
n16:J
n5:duvernostUdaju
n14:S
n5:entitaPredkladatele
n15:predkladatel
n5:idSjednocenehoVysledku
253775
n5:idVysledku
RIV/62156489:43210/10:00184801
n5:jazykVysledku
n8:cze
n5:klicovaSlova
cell line; marker; prostatic cells
n5:klicoveSlovo
n10:prostatic%20cells n10:cell%20line n10:marker
n5:kodStatuVydavatele
GB - Spojené království Velké Británie a Severního Irska
n5:kontrolniKodProRIV
[CAC215255A18]
n5:nazevZdroje
FEBS Journal
n5:obor
n11:CB
n5:pocetDomacichTvurcuVysledku
3
n5:pocetTvurcuVysledku
10
n5:projekt
n13:GP301%2F09%2FP436
n5:rokUplatneniVysledku
n7:2010
n5:svazekPeriodika
277
n5:tvurceVysledku
Kizek, René Kudláčková, V. Hrabec, Roman Masařík, Michal Křížková, Soňa Jurajda, Martin Rovný, Arne Gumulec, Jaromír Pavlík, Dušan Kuchtičková, S.
s:issn
1742-464X
s:numberOfPages
1
n12:organizacniJednotka
43210